- 2021
- Press releases - 19.05.2021
Many scientific studies have shown the health impacts of air pollution.
Many scientific studies have shown the health impacts of air pollution.
- Press releases - 17.05.2021
Arterial hypertension resistant to drug treatments: an international study demonstrates the blood pressure benefit of endovascular renal denervation by focused ultrasound
Teams from the Georges-Pompidou European Hospital AP-HP, the University of Paris, Inserm and the Presbyterian Hospital in New York carried out work to demonstrate the blood pressure benefit of endovascular renal denervation by focused ultrasound.
- News in brief - 11.05.2021
An Asthma Vaccine Effective in Mice
Inserm teams led by Laurent Reber (Infinity, Toulouse) and Pierre Bruhns (Humoral Immunity, Institut Pasteur, Paris) and French company NEOVACS have developed a vaccine that could induce long-term protection against allergic asthma, reducing the severity of its symptoms and thus significantly improving patient quality of life. Their research in animals has been published in the […]
- Press releases - 10.05.2021
Long COVID: 60% of Hospitalized Patients Still Have at Least One Symptom Six Months Later
In a new study, researchers show that a significant proportion of patients who were hospitalized and followed up as part of French COVID continue to have symptoms three and six months after infection.
- Press releases - 05.05.2021
COVID-19: discovery of the mechanisms of short- and long-term anosmia
Loss of smell, or anosmia, is one of the earliest and most commonly reported symptoms of COVID-19.
- Press releases - 05.05.2021
Cancers du foie de l’enfant : plasticité tumorale et résistance à la chimiothérapie
Grâce à une importante analyse génomique des cancers du foie de l’enfant, l’équipe du Professeure Jessica Zucman-Rossi au Centre de Recherche des Cordeliers (Université de Paris, Inserm, Sorbonne Université), et ses collaborateurs du réseau Hepatobio, ont identifié de nouveaux mécanismes de résistance à la chimiothérapie.
- Press releases - 29.04.2021
ComPaRe Covid long: development of the first scientific measure of the severity of the disease and its impact on the lives of patients
Researchers from the ComPaRe cohort (Community of Patients for Research, compare.aphp.fr ), led by Prof. Philippe Ravaud, AP-HP / University of Paris / Inserm, used an original method to develop and validate the first measurement science of the severity of the disease and its impact on the lives of patients.
- Press releases - 29.04.2021
Inserm and AstraZeneca join forces to test the efficacy of monoclonal antibody combination AZD7442 on Covid-19 in the European DisCoVeRy trial
A long-acting antibody (LAAB) combination developed by AstraZeneca is to be evaluated in DisCoVeRy, the Inserm-coordinated European trial aimed at finding a treatment for COVID-19.
- Press releases - 29.04.2021
EPIPAGE-2 Study: Outcomes for Preterm Children After 5.5 Years
A l’âge de 5 ans et demi, 35% des enfants nés extrêmes prématurés, près de 45% des grands prématurés et 55% de ceux nés modérément prématurés auront une trajectoire développementale proche de la normale.
- Press releases - 28.04.2021
COVIDOM – Study on the clinical characteristics and factors associated with hospitalization or death of ambulatory patients monitored remotely
Teams from AP-HP, Sorbonne University and Inserm at the Pierre Louis Institute of Epidemiology and Public Health, coordinated by Dr Youri Yordanov and Prof. Agnès Dechartres, assessed the clinical characteristics, fate and factors associated with hospitalization or death of ambulatory patients followed using the COVIDOM device.